Connection

CASSIAN YEE to Immunotherapy, Adoptive

This is a "connection" page, showing publications CASSIAN YEE has written about Immunotherapy, Adoptive.
Connection Strength

2.886
  1. Adoptive T cell therapy: points to consider. Curr Opin Immunol. 2018 04; 51:197-203.
    View in: PubMed
    Score: 0.302
  2. Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. Cancer J. 2017 Mar/Apr; 23(2):144-148.
    View in: PubMed
    Score: 0.279
  3. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol. 2016 11 01; 34(31):3787-3795.
    View in: PubMed
    Score: 0.273
  4. Endogenous T-Cell Therapy: Clinical Experience. Cancer J. 2015 Nov-Dec; 21(6):492-500.
    View in: PubMed
    Score: 0.254
  5. Adoptive therapy using antigen-specific T-cell clones. Cancer J. 2010 Jul-Aug; 16(4):367-73.
    View in: PubMed
    Score: 0.176
  6. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One. 2009; 4(3):e4749.
    View in: PubMed
    Score: 0.160
  7. Adoptive T-cell therapy of cancer. Hematol Oncol Clin North Am. 2006 Jun; 20(3):711-33.
    View in: PubMed
    Score: 0.132
  8. Letter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapy. J Immunother Cancer. 2023 04; 11(4).
    View in: PubMed
    Score: 0.106
  9. Adoptive T cell therapy--immune monitoring and MHC multimers. Clin Immunol. 2003 Jan; 106(1):5-9.
    View in: PubMed
    Score: 0.105
  10. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002 Dec 10; 99(25):16168-73.
    View in: PubMed
    Score: 0.103
  11. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.093
  12. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.093
  13. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000 Dec 04; 192(11):1637-44.
    View in: PubMed
    Score: 0.090
  14. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer. 2020 04; 8(1).
    View in: PubMed
    Score: 0.086
  15. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 06; 8(6):794-805.
    View in: PubMed
    Score: 0.086
  16. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e70-e78.
    View in: PubMed
    Score: 0.081
  17. Prospects for adoptive T cell therapy. Curr Opin Immunol. 1997 Oct; 9(5):702-8.
    View in: PubMed
    Score: 0.073
  18. The use of endogenous T cells for adoptive transfer. Immunol Rev. 2014 Jan; 257(1):250-63.
    View in: PubMed
    Score: 0.056
  19. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res. 2014 Jan; 2(1):27-36.
    View in: PubMed
    Score: 0.056
  20. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother. 2012 Feb-Mar; 35(2):131-41.
    View in: PubMed
    Score: 0.049
  21. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1664-73.
    View in: PubMed
    Score: 0.046
  22. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6.
    View in: PubMed
    Score: 0.030
  23. Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling. CPT Pharmacometrics Syst Pharmacol. 2023 11; 12(11):1577-1590.
    View in: PubMed
    Score: 0.027
  24. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003 May; 3(5):431-7.
    View in: PubMed
    Score: 0.027
  25. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest. 2002 Nov; 110(10):1415-7.
    View in: PubMed
    Score: 0.026
  26. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 05 02; 28(9):1911-1924.
    View in: PubMed
    Score: 0.025
  27. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun. 2020 10 21; 11(1):5332.
    View in: PubMed
    Score: 0.022
  28. Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy. Ciba Found Symp. 1994; 187:212-23; discussion 224-8.
    View in: PubMed
    Score: 0.014
  29. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res. 2013 Apr 15; 73(8):2598-607.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.